The Turning Point in Pancreatic Cancer is Here
PanCAN launched a $250 million campaign to accelerate pancreatic cancer research, citing breakthroughs in KRAS targeted therapy and mRNA vaccines. Recent clinical trials have shown promising results, with patients living approximately twice as long as those receiving standard chemotherapy.
PanCAN, a pancreatic cancer organization, has launched a five-year, $250 million campaign to accelerate research and improve patient outcomes. The organization cites recent breakthroughs in KRAS targeted therapy and mRNA vaccines as evidence of progress. A clinical trial testing daraxonrasib, a KRAS-targeting oral therapy, showed patients with previously treated metastatic disease lived approximately twice as long as those receiving standard chemotherapy. Emerging mRNA vaccines are also showing promising early results. PanCAN has invested over $249 million in research and has contributed to the development of multiple KRAS-targeting strategies over the past twenty years. The organization's efforts have helped reshape the national research landscape, increasing federal funding and attention for pancreatic cancer.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.